GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Forward PE Ratio

Zymeworks (Zymeworks) Forward PE Ratio : 0.00 (As of May. 17, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Forward PE Ratio?

Zymeworks's Forward PE Ratio for today is 0.00.

Zymeworks's PE Ratio without NRI for today is 0.00.

Zymeworks's PE Ratio for today is 0.00.


Zymeworks Forward PE Ratio Historical Data

The historical data trend for Zymeworks's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Forward PE Ratio Chart

Zymeworks Annual Data
Trend
Forward PE Ratio

Zymeworks Quarterly Data
Forward PE Ratio

Competitive Comparison of Zymeworks's Forward PE Ratio

For the Biotechnology subindustry, Zymeworks's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's Forward PE Ratio falls into.



Zymeworks Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Zymeworks  (NAS:ZYME) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Zymeworks Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Zymeworks's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (Zymeworks) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Executives
Paul Andrew Moore officer: Chief Scientific Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle officer: SVP & Chief Financial Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith director, officer: Chair & CEO OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy director 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael director 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas officer: President & COO 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Troy Cox director C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton director
Kelvin Neu director 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson officer: Chief Medical Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4

Zymeworks (Zymeworks) Headlines